KemPharm, Inc.

171 articles with KemPharm, Inc.

• CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

  5/17/2022

  CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).

• KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

  5/16/2022

  KemPharm, Inc. announced a definitive agreement with Orphazyme A/S to acquire arimoclomol, an orally-delivered, first-in-class heat shock protein amplifier being developed as a treatment for Niemann-Pick disease type C.

• 

  KemPharm Acquires Majority of Orphazyme Assets Under In-Court Restructuring

  5/16/2022

  Orphazyme has several products with potential, with biopharma company KemPharm acquiring nearly all of the company's assets and operations. 

• Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

  5/15/2022

  Orphazyme A/S in restructuring, a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C, announces that it has signed an agreement to sell substantially all of the Company’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc.

• KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates

  5/12/2022

  KemPharm, Inc., a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system and neurodegenerative diseases, reported its financial results for the first quarter ended March 31, 2022.

• KemPharm to Present at Multiple Upcoming Investor Conferences

  5/11/2022

  KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that members of management will participate in three upcoming in-person investor conferences.

• KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

  5/5/2022

  KemPharm, Inc.  today announced the submission of an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Administration.

• KemPharm to Report First Quarter 2022 Financial Results

  5/4/2022

  KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that the Company will host a conference call and live audio webcast on Thursday, May 12, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the first quarter 2022.

• KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

  4/19/2022

  KemPharm, Inc. today announced that the first subject has been dosed in a Phase 1 clinical trial designed to assess the relative cardiovascular safety of serdexmethylphenidate (SDX) compared to immediate-release and long-acting formulations of Ritalin® (racemic methylphenidate).

• KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates

  3/30/2022

  KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today reported its financial results for the fourth quarter and year ended December 31, 2021.

• 

  Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and Much More

  3/28/2022

  Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.

• KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference

  3/24/2022

  KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at Maxim’s 2022 Virtual Growth Conference being held March 28-30, 2022.

• KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial

  3/21/2022

  KemPharm, Inc. today announced that the Company has completed its analysis of the full data set from its Phase 1 clinical trial exploring the safety and pharmacokinetics (PK) of serdexmethylphenidate (SDX) delivered at doses higher than those previously studied.

• KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)

  3/16/2022

  KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), today announced that the Company has earned a $1.975 million fee from Corium, Inc., (Corium), a portfolio company of Gurnet Point Capital, following the approval of Corium’s product ADLARITY® (donepezil transdermal system) by the U.S. Food and Drug Administration (FDA) on March 11, 2022.

• KemPharm to Report Fourth Quarter and Full-Year 2021 Results

  3/10/2022

  Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022, 5:00 p.m. ET.

• KemPharm Completes KP1077 Pre-IND Meeting Process with FDA

  2/23/2022

  KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022.

• KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy

  1/19/2022

  KemPharm, Inc. announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders detailing the company’s strategic focus on Central Nervous System /Rare Disease indications, as well as an updated clinical development strategy.

• KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion

  1/12/2022

  KemPharm, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, January 19, 2022, at 4:30 p.m. ET, to discuss the Company’s strategy for advancing and expanding its development pipeline.

• KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference

  1/11/2022

  KemPharm, Inc., announced that research involving serdexmethylphenidate, the company’s proprietary prodrug of d-methylphenidate, will be featured in two poster presentations during the American Professional Society of ADHD and Related Disorders 2022 Annual Conference being held virtually January 13-16, 2022.

• KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”

  1/6/2022

  KemPharm, Inc. announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.